卡培他滨联合奥沙利铂治疗晚期胃癌的临床疗效

发布时间：2018-04-04 23:00

本文选题：卡培他滨　切入点：奥沙利铂　出处：《中国地方病防治杂志》2017年08期

【摘要】：目的探讨卡培他滨联合奥沙利铂治疗晚期胃癌的临床疗效和安全性。方法采用前瞻性临床研究方法,将2013年1月-2015年12月于我院保守治疗的100例晚期胃癌患者分为观察组和对照组,每组50例。观察组患者给予卡培他滨联合奥沙利铂治疗,对照组患者给予卡培他滨联合多西他赛治疗。治疗3个周期后,比较不同方案的临床效果、肿瘤标志物水平、安全性和患者生存质量评分等。结果经不同方案的化疗药物治疗后,在总有效率方面,观察组(84%)明显高于对照组(62%),差异具有统计学意义(P0.05);在疾病控制率方面,观察组(94%)高于对照组(80%),但差异无统计学意义(P0.05);在肿瘤标志物水平方面,观察组明显低于对照组,差异具有统计学意义(P0.05)。观察组的药物不良反应发生率(12%)低于对照组(16%),但差异无统计学意义。治疗前,两组患者在生存质量评分方面的差异无统计学意义;治疗后,观察组患者对生存质量的评分明显高于对照组,差异具有统计学意义(P0.05)。结论卡培他滨联合奥沙利铂治疗晚期胃癌的临床效果优于卡培他滨联合多西他赛治疗,且患者的预后生存质量较高。
[Abstract]:Objective to evaluate the efficacy and safety of capecitabine combined with oxaliplatin in the treatment of advanced gastric cancer.Methods 100 patients with advanced gastric cancer who were treated conservatively in our hospital from January 2013 to December 2015 were divided into observation group (n = 50) and control group (n = 50).Patients in the observation group were treated with capecitabine combined with oxaliplatin and those in the control group were treated with capecitabine combined with docetaxel.After 3 cycles of treatment, the clinical effect, tumor marker level, safety and quality of life score of patients with different regimens were compared.Results the total effective rate of the observation group was significantly higher than that of the control group (P 0.05), and the disease control rate was higher than that of the control group (P 0.05).The observation group was higher than the control group, but the difference was not statistically significant (P 0.05), and the level of tumor markers in the observation group was significantly lower than that in the control group (P 0.05).The incidence of adverse drug reactions in the observation group was lower than that in the control group, but the difference was not statistically significant.Before treatment, there was no significant difference in quality of life score between the two groups; after treatment, the score of quality of life in the observation group was significantly higher than that in the control group, and the difference was statistically significant (P 0.05).Conclusion Capecitabine combined with oxaliplatin is more effective than capecitabine combined with docetaxel in the treatment of advanced gastric cancer, and the quality of life of patients with advanced gastric cancer is higher than that of capecitabine combined with docetaxel.
【作者单位】：西安医学院第二附属医院;
【分类号】：R735.2

【相似文献】